Bursledon Hall
Blundell Lane 
Southampton 
S031 lAA 
Telephone: (023) 80408615 	
Fax: (023) 8040 8609 Email: dare@dsru.org http://www.dsru.org 

Dear Colleague

Drug-Induced Arrhythmia Risk Evaluation:  The DARE Study 

This study of the epidemiology, clinical risks and genetic basis of drug-induced ventricular arrhythmias is now in its 4th year. We have had to deal with many unforeseen hurdles caused by NHS R&D department guidelines, which slowed the study’s momentum. Fortunately we are now over many of these barriers and while your assistance so far has been greatly appreciated, we hope to remind you of our ongoing efforts and the importance of your continued support. Inclusion criteria will be at least one of the following, diagnosed as secondary to therapeutic drug administration or overdosage:
•	Documented TdP, VF, polymorphic VT or non-polymorphic VT  

•	Exacerbation of an already existent ventricular arrhythmia

•	Severe QT prolongation (corrected QT interval  500ms)

•	Moderate drug-induced QT interval prolongation (QT interval  450ms [male patient] 
or  470ms [female patient] and a clinical history of presyncope or syncope

If you feel you have such a case, please contact 02380 408615 or dare@dsru.org and we will be delighted to arrange a personal visit from your regional DARE Study research nurse to assist your referral and provide you with any information necessary.
Yours sincerely,							

									        

Professor Saad A W Shakir MB ChB				 Professor A J Camm QHP BSc MD
LRCP&S FRCP FFPM MRCGP	FRCP FESC FACC FAHA FCGC CStJ
Director Drug Safety Research Unit				 Professor of Clinical Cardiology

The Drug Safety Research Unit is an independent registered charity (No.327206), which works in association with the University of Portsmouth. This is a collaborative project between the Drug Safety Research Unit and St George's Hospital Medical School, London. The study is funded by the British Heart Foundation (Registered Charity No.225971).